MX392634B - Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo - Google Patents

Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo

Info

Publication number
MX392634B
MX392634B MX2019012574A MX2019012574A MX392634B MX 392634 B MX392634 B MX 392634B MX 2019012574 A MX2019012574 A MX 2019012574A MX 2019012574 A MX2019012574 A MX 2019012574A MX 392634 B MX392634 B MX 392634B
Authority
MX
Mexico
Prior art keywords
preparing
crystalline form
salt
aminopyridine
compound derived
Prior art date
Application number
MX2019012574A
Other languages
English (en)
Spanish (es)
Inventor
Dong Kyun Kim
Hyun Ju
Jeong Ki Kang
Jong Gyun Kim
Kyeong Bae Kim
Sang Ho Oh
Se- Woong OH
Seong Ran Lee
Soo Yong Chung
Su Min Park
Tae Dong Han
Woo Seob Shin
Young Sung Lee
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX392634(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX392634B publication Critical patent/MX392634B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2019012574A 2017-04-21 2018-04-18 Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo MX392634B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21
PCT/KR2018/004473 WO2018194356A1 (en) 2017-04-21 2018-04-18 Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same

Publications (1)

Publication Number Publication Date
MX392634B true MX392634B (es) 2025-03-24

Family

ID=63857137

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012574A MX392634B (es) 2017-04-21 2018-04-18 Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo
MX2022006357A MX2022006357A (es) 2017-04-21 2019-10-21 Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006357A MX2022006357A (es) 2017-04-21 2019-10-21 Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo.

Country Status (23)

Country Link
US (3) US11453656B2 (enExample)
EP (1) EP3612529A4 (enExample)
JP (2) JP7126514B2 (enExample)
KR (3) KR102629654B1 (enExample)
CN (1) CN110869367B (enExample)
AR (1) AR111469A1 (enExample)
AU (2) AU2018256227B2 (enExample)
BR (1) BR112019021868A2 (enExample)
CA (1) CA3059543A1 (enExample)
CO (1) CO2019011578A2 (enExample)
EA (1) EA201992501A1 (enExample)
IL (2) IL294666B2 (enExample)
MA (1) MA49696A (enExample)
MX (2) MX392634B (enExample)
MY (1) MY201919A (enExample)
NZ (1) NZ758443A (enExample)
PH (1) PH12019502370A1 (enExample)
SA (1) SA519410342B1 (enExample)
SG (1) SG11201909615YA (enExample)
TW (1) TWI776882B (enExample)
UA (1) UA124364C2 (enExample)
WO (1) WO2018194356A1 (enExample)
ZA (1) ZA201907687B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MD3658552T2 (ro) 2017-07-28 2024-02-29 Yuhan Corp Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
EP3885346A4 (en) * 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
EP3931224A4 (en) 2019-02-26 2023-03-01 Janssen Biotech, Inc. COMBINATION TREATMENTS AND PATIENT STRATIFICATION WITH ANTI-EGFR/C-MET BISPECIFIC ANTIBODIES
MX2021013955A (es) * 2019-05-14 2022-03-11 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación.
WO2020230091A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
WO2022253261A1 (zh) 2021-06-01 2022-12-08 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech Inc Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063713A1 (ja) 2003-12-25 2005-07-14 Eisai Co., Ltd. 4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩またはその溶媒和物の結晶およびそれらの製造方法
CA2555804C (en) 2004-02-11 2012-06-26 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
NZ624345A (en) * 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
EP2498607B1 (en) * 2009-11-13 2016-02-17 Genosco Kinase inhibitors
EP2649060B1 (en) * 2010-12-06 2017-04-05 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
EP3333161B1 (en) 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
CN106687457B (zh) 2014-05-13 2020-01-10 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
SI3604294T1 (sl) * 2014-10-13 2021-08-31 Yuhan Corporation Spojine in sestavki za moduliranje aktivnosti kinaze mutanta EGFR
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Also Published As

Publication number Publication date
ZA201907687B (en) 2023-04-26
KR20180118535A (ko) 2018-10-31
AR111469A1 (es) 2019-07-17
WO2018194356A1 (en) 2018-10-25
US20210139461A1 (en) 2021-05-13
US11453656B2 (en) 2022-09-27
TW201841910A (zh) 2018-12-01
IL270018A (enExample) 2019-12-31
AU2018256227B2 (en) 2022-03-03
EP3612529A4 (en) 2020-11-18
AU2018256227A1 (en) 2019-10-31
EA201992501A1 (ru) 2020-02-18
US12428401B2 (en) 2025-09-30
CA3059543A1 (en) 2018-10-25
PH12019502370A1 (en) 2020-07-13
UA124364C2 (uk) 2021-09-01
KR20230175161A (ko) 2023-12-29
JP2020517611A (ja) 2020-06-18
MY201919A (en) 2024-03-23
MX2022006357A (es) 2022-06-23
US20230021395A1 (en) 2023-01-26
AU2022203486A1 (en) 2022-06-09
JP7390444B2 (ja) 2023-12-01
TWI776882B (zh) 2022-09-11
US20240279203A1 (en) 2024-08-22
IL294666B1 (en) 2024-01-01
CN110869367A (zh) 2020-03-06
AU2022203486B2 (en) 2024-06-06
IL294666B2 (en) 2024-05-01
SG11201909615YA (en) 2019-11-28
KR102835717B1 (ko) 2025-07-18
KR102629654B1 (ko) 2024-01-29
IL294666A (en) 2022-09-01
JP2022166179A (ja) 2022-11-01
CO2019011578A2 (es) 2020-02-28
US11981659B2 (en) 2024-05-14
MA49696A (fr) 2020-06-03
BR112019021868A2 (pt) 2020-05-26
SA519410342B1 (ar) 2023-02-09
EP3612529A1 (en) 2020-02-26
NZ758443A (en) 2023-03-31
KR20250111074A (ko) 2025-07-22
CN110869367B (zh) 2023-09-15
IL270018B (en) 2022-08-01
JP7126514B2 (ja) 2022-08-26

Similar Documents

Publication Publication Date Title
MX392634B (es) Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta y un proceso para prepararlo
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
MX391812B (es) Agonista fxr derivado de esteroides.
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
CL2021002365A1 (es) Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas
EA201692298A1 (ru) Производные карбоксамидов
MX2021010016A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
EA201992153A1 (ru) Гетероарилтрифторборатные соединения для лечения микобактериальных инфекций
TH152519A (th) อนุพันธ์อัลริลเอทธินิล
PH12016502247A1 (en) Carboxamide derivatives
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль